bw a522 has been researched along with quinazolines in 1 studies
| Studies (bw a522) | Trials (bw a522) | Recent Studies (post-2010) (bw a522) | Studies (quinazolines) | Trials (quinazolines) | Recent Studies (post-2010) (quinazolines) |
|---|---|---|---|---|---|
| 10 | 0 | 0 | 19,235 | 2,417 | 8,835 |
| Protein | Taxonomy | bw a522 (IC50) | quinazolines (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.027 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jones, CA; Reeves, JJ; Sheehan, MJ; Vardey, CJ; Whelan, CJ | 1 |
1 other study(ies) available for bw a522 and quinazolines
| Article | Year |
|---|---|
Adenosine A3 receptors promote degranulation of rat mast cells both in vitro and in vivo.
Topics: Adenosine; Administration, Cutaneous; Animals; Blood Proteins; Cell Degranulation; Cyproheptadine; Dinitrophenols; Female; Humans; In Vitro Techniques; Injections, Intravenous; Male; Mast Cells; Mice; p-Methoxy-N-methylphenethylamine; Pleura; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Quinazolines; Rats; Rats, Wistar; Receptors, Purinergic P1; Serotonin; Serotonin Antagonists; Serum Albumin; Skin; Theophylline; Triazoles; Xanthines | 1997 |